HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

A retrospective study found that women who took a GLP-1 drug for obesity were more likely to be diagnosed with acne vulgaris ...

Finding natural ways to increase glucagon-like peptide-1, otherwise known as GLP-1, can be very beneficial in helping treat type 2 diabetes and obesity.

Ypsomed and Sidekick Health are launching an integrated digital health solution to better support people with obesity.

RANI READ THE FULL RANI RESEARCH REPORT On March 31 st , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported 2024 results. Since the third quarter report, Rani has participated in multiple ...

The A1C test measures a person’s average blood glucose or blood sugar levels over the past 3 months. An A1C reading of over 5.6% may be a cause for concern, but this will depend on various ...

Pipeline Highlights and Upcoming Milestones MET-097i rapidly advancing towards Phase 3 MET-097i is a fully biased, monthly, ultra-long acting, potent, subcutaneously injectable GLP-1 receptor ...

small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for obesity The FALCON Phase 2 clinical trial enrolled its first patient in March 2025, with 12-week data expected in the fourth quarter ...

small-molecule GLP-1R agonists in a 12-week study Slower titration aims to achieve competitive 12-week weight loss, best-in-class tolerability and simplest titration amongst the oral, small ...

small-molecule GLP-1R agonists in a 12-week study Slower titration aims to achieve competitive 12-week weight loss, best-in-class tolerability and simplest titration amongst the oral, small ...